Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jerry Bagel

Showing results (51-60 of 100) with videos related to

Pageof 10
Sort By:
Journal of Medical Economics|June 10, 2021
Dose escalation and associated costs in biologic treatment of psoriasis based on real-world dataJerry Bagel, Brad Glick, Jashin J Wu, et al.
Journal of the American Academy of Dermatology|December 24, 2008
Treatment of intertriginous psoriasis: from the Medical Board of the National Psoriasis FoundationRobert E Kalb, Jerry Bagel, Neil J Korman, et al.
Journal of the American Academy of Dermatology|November 5, 2013
From the Medical Board of the National Psoriasis Foundation: The risk of cardiovascular disease in individuals with psoriasis and the potential impact of current therapiesJeremy Hugh, Abby S Van Voorhees, Rajiv I Nijhawan, et al.
American Journal of Clinical Dermatology|August 28, 2019
Treatment of Medicare Patients with Moderate-to-Severe Psoriasis who Cannot Afford Biologics or ApremilastNicola E Natsis, Joseph F Merola, Jeffrey M Weinberg, et al.
Journal of Drugs in Dermatology : JDD|August 7, 2025
Comparative Efficacy of Deucravacitinib and Adalimumab for Scalp Psoriasis: An Indirect Treatment ComparisonVardhaman Patel, Alexa Hetzel, Sang Hee Park, et al.
Dermatology and Therapy|September 16, 2024
Impact of Disease Burden of Patients with Psoriasis on Biologic Therapy Switching: Real-World Evidence from the CorEvitas Psoriasis RegistryAndrew Blauvelt, Robert R McLean, Silky W Beaty, et al.
Journal of the American Academy of Dermatology|August 7, 2017
The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24-week, randomized, double-blind, placebo-controlled phase 3b studyJerry Bagel, Kristina Callis Duffin, Angela Moore, et al.
Journal of the American Academy of Dermatology|May 13, 2019
Brodalumab in the treatment of moderate to severe psoriasis in patients when previous anti-interleukin 17A therapies have failedGrace Kimmel, Margot Chima, Hee Jin Kim, et al.
BMC Rheumatology|December 5, 2019
Serious infections in patients with self-reported psoriatic arthritis from the Psoriasis Longitudinal Assessment and Registry (PSOLAR) treated with biologicsChristopher T Ritchlin, Mona Stahle, Yves Poulin, et al.
Journal of Drugs in Dermatology : JDD|August 16, 2017
Efficacy and Safety of Apremilast in Patients With Moderate Plaque Psoriasis With Lower BSA: Week 16 Results from the UNVEIL StudyBruce Strober, Jerry Bagel, Mark Lebwohl, et al.
Pageof 10

Showing results (51-60 of 100) with videos related to

Sort By:
Pageof 10
Journal of Medical Economics|June 10, 2021
Dose escalation and associated costs in biologic treatment of psoriasis based on real-world dataJerry Bagel, Brad Glick, Jashin J Wu, et al.
Journal of the American Academy of Dermatology|December 24, 2008
Treatment of intertriginous psoriasis: from the Medical Board of the National Psoriasis FoundationRobert E Kalb, Jerry Bagel, Neil J Korman, et al.
Journal of the American Academy of Dermatology|November 5, 2013
From the Medical Board of the National Psoriasis Foundation: The risk of cardiovascular disease in individuals with psoriasis and the potential impact of current therapiesJeremy Hugh, Abby S Van Voorhees, Rajiv I Nijhawan, et al.
American Journal of Clinical Dermatology|August 28, 2019
Treatment of Medicare Patients with Moderate-to-Severe Psoriasis who Cannot Afford Biologics or ApremilastNicola E Natsis, Joseph F Merola, Jeffrey M Weinberg, et al.
Journal of Drugs in Dermatology : JDD|August 7, 2025
Comparative Efficacy of Deucravacitinib and Adalimumab for Scalp Psoriasis: An Indirect Treatment ComparisonVardhaman Patel, Alexa Hetzel, Sang Hee Park, et al.
Dermatology and Therapy|September 16, 2024
Impact of Disease Burden of Patients with Psoriasis on Biologic Therapy Switching: Real-World Evidence from the CorEvitas Psoriasis RegistryAndrew Blauvelt, Robert R McLean, Silky W Beaty, et al.
Journal of the American Academy of Dermatology|August 7, 2017
The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24-week, randomized, double-blind, placebo-controlled phase 3b studyJerry Bagel, Kristina Callis Duffin, Angela Moore, et al.
Journal of the American Academy of Dermatology|May 13, 2019
Brodalumab in the treatment of moderate to severe psoriasis in patients when previous anti-interleukin 17A therapies have failedGrace Kimmel, Margot Chima, Hee Jin Kim, et al.
BMC Rheumatology|December 5, 2019
Serious infections in patients with self-reported psoriatic arthritis from the Psoriasis Longitudinal Assessment and Registry (PSOLAR) treated with biologicsChristopher T Ritchlin, Mona Stahle, Yves Poulin, et al.
Journal of Drugs in Dermatology : JDD|August 16, 2017
Efficacy and Safety of Apremilast in Patients With Moderate Plaque Psoriasis With Lower BSA: Week 16 Results from the UNVEIL StudyBruce Strober, Jerry Bagel, Mark Lebwohl, et al.
Pageof 10